Literature DB >> 24026318

A prospective assessment defining the limitations of thyroid nodule pathologic evaluation.

Edmund S Cibas, Zubair W Baloch, Giovanni Fellegara, Virginia A LiVolsi, Stephen S Raab, Juan Rosai, James Diggans, Lyssa Friedman, Giulia C Kennedy, Richard T Kloos, Richard B Lanman, Susan J Mandel, Nicole Sindy, David L Steward, Martha A Zeiger, Bryan R Haugen, Erik K Alexander.   

Abstract

BACKGROUND: Clinical management of thyroid neoplasms is based on light microscopic diagnosis, but its accuracy and precision are poorly defined.
OBJECTIVE: To assess inter- and intraobserver variability of preoperative cytopathologic and postoperative histopathologic thyroid diagnoses.
DESIGN: Samples were collected in a prospective, multicenter trial validating a gene expression classifier between June 2009 and December 2010.
SETTING: 14 academic and 35 community clinical sites. PATIENTS: 653 patients with 776 surgically resected thyroid nodules of 1 cm or greater. MEASUREMENTS: Intraobserver concordance among 2 or more central histopathologists who independently read histopathology slides was calculated. Interobserver concordance between the diagnoses made by the central histopathologists and those made by local pathologists were calculated. Intra- and interobserver concordance for cytopathology was similarly calculated by comparing diagnoses made by local pathologists with those made by a central panel of 3 cytopathologists.
RESULTS: Concordance on the histopathologic distinction between benign and malignant diagnoses was 91% comparing local with central histopathologists and 90% comparing 2 central histopathologists. Using the 6-category Bethesda System, 64.0% of diagnoses made by local and central cytopathologists and 74.7% of intraobserver diagnoses were concordant. Central cytopathologists made fewer indeterminate diagnoses than local pathologists (41.2% vs. 55.0%). LIMITATIONS: Many local pathologists did not use the Bethesda System, so their reports were translated to allow comparison. The study required histopathology, and the study population and specimens did not encompass all newly evaluated patients with a thyroid nodule.
CONCLUSION: Substantial inter- and intraobserver variability exists in the cytopathologic and histopathologic evaluation of thyroid nodules, confirming an inherent limitation of visual microscopic diagnosis. PRIMARY FUNDING SOURCE: Veracyte.

Entities:  

Mesh:

Year:  2013        PMID: 24026318     DOI: 10.7326/0003-4819-159-5-201309030-00006

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN: 0003-4819            Impact factor:   25.391


  54 in total

1.  Cytopathology of Follicular Cell Nodules.

Authors:  Domenico Damiani; Voichita Suciu; Philippe Vielh
Journal:  Endocr Pathol       Date:  2015-12       Impact factor: 3.943

2.  Is serum TSH a biomarker of thyroid carcinoma in patients residing in a mildly iodine-deficient area?

Authors:  Kristine Zøylner Swan; Viveque Egsgaard Nielsen; Christian Godballe; Jens Faunø Thrane; Marie Riis Mortensen; Sten Schytte; Henrik Baymler Pedersen; Peer Christiansen; Steen Joop Bonnema
Journal:  Endocrine       Date:  2018-05-31       Impact factor: 3.633

3.  Performance of a Genomic Sequencing Classifier for the Preoperative Diagnosis of Cytologically Indeterminate Thyroid Nodules.

Authors:  Kepal N Patel; Trevor E Angell; Joshua Babiarz; Neil M Barth; Thomas Blevins; Quan-Yang Duh; Ronald A Ghossein; R Mack Harrell; Jing Huang; Giulia C Kennedy; Su Yeon Kim; Richard T Kloos; Virginia A LiVolsi; Gregory W Randolph; Peter M Sadow; Michael H Shanik; Julie A Sosa; S Thomas Traweek; P Sean Walsh; Duncan Whitney; Michael W Yeh; Paul W Ladenson
Journal:  JAMA Surg       Date:  2018-09-01       Impact factor: 14.766

4.  Comparison of two different standards of care in detecting malignant thyroid nodules using thyroid fine-needle aspiration.

Authors:  Xiaoyun Liu; Lijun Zhu; Zhixiao Wang; Dai Cui; Huanhuan Chen; Ling Wei; Yunsong Wu; Rong Rong; Yan Wu; Qing Yao; Zhihong Zhang; Edmund S Cibas; Erik K Alexander; Tao Yang
Journal:  Mol Clin Oncol       Date:  2015-01-22

5.  Afirma Gene Sequencing Classifier Compared with Gene Expression Classifier in Indeterminate Thyroid Nodules.

Authors:  Mayumi Endo; Fadi Nabhan; Kyle Porter; Katie Roll; Lawrence A Shirley; Irina Azaryan; Dena Tonkovich; Jeanette Perlick; Laura E Ryan; Raheela Khawaja; Shumei Meng; John E Phay; Matthew D Ringel; Jennifer A Sipos
Journal:  Thyroid       Date:  2019-07-17       Impact factor: 6.568

Review 6.  Molecular profiling of thyroid nodule fine-needle aspiration cytology.

Authors:  Markus Eszlinger; Lorraine Lau; Sana Ghaznavi; Christopher Symonds; Shamir P Chandarana; Moosa Khalil; Ralf Paschke
Journal:  Nat Rev Endocrinol       Date:  2017-03-31       Impact factor: 43.330

7.  Thyroid Nodules with Indeterminate Cytology: Utility of the American Thyroid Association Sonographic Patterns for Cancer Risk Stratification.

Authors:  Pablo Valderrabano; Melissa J McGettigan; Cesar A Lam; Laila Khazai; Zachary J Thompson; Christine H Chung; Barbara A Centeno; Bryan McIver
Journal:  Thyroid       Date:  2018-07-17       Impact factor: 6.568

8.  Circulating Myeloid-Derived Suppressor Cells Predict Differentiated Thyroid Cancer Diagnosis and Extent.

Authors:  Trevor E Angell; Melissa G Lechner; Alison M Smith; Sue E Martin; Susan G Groshen; Dennis R Maceri; Peter A Singer; Alan L Epstein
Journal:  Thyroid       Date:  2016-02-10       Impact factor: 6.568

Review 9.  Thyroid nodules and cancer management guidelines: comparisons and controversies.

Authors:  Fadi Nabhan; Matthew D Ringel
Journal:  Endocr Relat Cancer       Date:  2016-12-13       Impact factor: 5.678

10.  Proposal for a novel management of indeterminate thyroid nodules on the basis of cytopathological subclasses.

Authors:  Martina Rossi; Sabrina Lupo; Roberta Rossi; Paola Franceschetti; Giorgio Trasforini; Stefania Bruni; Federico Tagliati; Mattia Buratto; Giovanni Lanza; Luca Damiani; Ettore Degli Uberti; Maria Chiara Zatelli
Journal:  Endocrine       Date:  2016-09-13       Impact factor: 3.633

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.